CARE Trial: Difference between revisions
Rim Halaby (talk | contribs) Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==CARE Trial== ===Objective=== To assess if pravastatin would reduce the sum of fatal coronary artery disease (CAD)..." |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Objective== | |||
To assess if [[pravastatin]] would reduce the sum of fatal [[coronary artery disease]] ([[CAD]]) and nonfatal myocardial infarction (MI) in patients who had a previous MI and a total cholesterol value < 240 mg/dl. | To assess if [[pravastatin]] would reduce the sum of fatal [[coronary artery disease]] ([[CAD]]) and nonfatal myocardial infarction (MI) in patients who had a previous MI and a total cholesterol value < 240 mg/dl. | ||
==Methods== | |||
Cholesterol and Recurrent Events trial was a double blinded, randomized study wherein 4159 patients with a history of a myocardial infarction in the previous two years who had a total cholesterol value < 240 mg/dl were enrolled and treated with either 40 mg pravastatin or a [[placebo]]. | Cholesterol and Recurrent Events trial was a double blinded, randomized study wherein 4159 patients with a history of a myocardial infarction in the previous two years who had a total cholesterol value < 240 mg/dl were enrolled and treated with either 40 mg pravastatin or a [[placebo]]. | ||
==Results== | |||
The following results were obtained after a median follow-up time of 5 years: | The following results were obtained after a median follow-up time of 5 years: | ||
* Reduced combined end point of coronary death and nonfatal [[MI]] (10.2 versus 13.2 percent) | * Reduced combined end point of coronary death and nonfatal [[MI]] (10.2 versus 13.2 percent) | ||
| Line 22: | Line 21: | ||
[[Category:Lipopedia]] | [[Category:Lipopedia]] | ||
[[Category:HDL]] | [[Category:HDL]] | ||
[[Category:Clinical trials]] | |||
Revision as of 23:29, 17 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
CARE Trial On the Web |
|
American Roentgen Ray Society Images of CARE Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
To assess if pravastatin would reduce the sum of fatal coronary artery disease (CAD) and nonfatal myocardial infarction (MI) in patients who had a previous MI and a total cholesterol value < 240 mg/dl.
Methods
Cholesterol and Recurrent Events trial was a double blinded, randomized study wherein 4159 patients with a history of a myocardial infarction in the previous two years who had a total cholesterol value < 240 mg/dl were enrolled and treated with either 40 mg pravastatin or a placebo.
Results
The following results were obtained after a median follow-up time of 5 years:
- Reduced combined end point of coronary death and nonfatal MI (10.2 versus 13.2 percent)
- Reduced need for revascularization with CABG or PTCA (14.1 versus 18.8 percent)
- Reduced frequency of stroke (2.6 versus 3.8 percent) and of stroke plus transient ischemic attacks (4.4 versus 6.0 percent)[1][2]
References
- ↑ Sacks FM, Pfeffer MA, Moye LA; et al. (1996). "The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators". The New England Journal of Medicine. 335 (14): 1001–9. doi:10.1056/NEJM199610033351401. PMID 8801446. Unknown parameter
|month=ignored (help) - ↑ Pfeffer MA, Sacks FM, Moyé LA; et al. (1995). "Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators". The American Journal of Cardiology. 76 (9): 98C–106C. PMID 7572695. Unknown parameter
|month=ignored (help)